Table 4. Results of association analyses using combined SJS/TEN patients' data.
| a. Comparison between CM-SJS/TEN with SOC (Group 1a and Group 2a) and combined healthy volunteers' data | ||||
|---|---|---|---|---|
| HLA genotype | Carrier frequency (%) | Dominant model analysis | ||
| CM-SJS/TEN with SOC (Group 1a and Group 2a) | Control (Combined healthy controls) | p | Odds ratio (95% CI) | |
| A*02:06 | 71/151 (47.0%) | 87/639 (13.6%) | 2.72E-20 | 5.63 (3.81–8.33) |
| B*44:03 | 39/151 (25.8%) | 95/639 (14.9%) | 0.00125 | 1.99 (1.30–3.05) |
*Woolf's correction.
P: P values obtained by χ2-tests.
CM-SJS/TEN: cold medicine related SJS/TEN who had taken cold medicine.
SOC: severe ocular surface complications.
CI: Confidence interval.